{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T05:29:20Z","timestamp":1782019760554,"version":"3.54.5"},"reference-count":46,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2016,6,15]],"date-time":"2016-06-15T00:00:00Z","timestamp":1465948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:p>About 105 consecutive acute myeloid leukemia (AML) patients treated with the same induction\u2010consolidation program between 2004 and 2013 were retrospectively analyzed. Median age was 47 years. The first induction course included fludarabine (Flu) and high\u2010dose cytarabine (Ara\u2010C) plus idarubicin (Ida), with or without gemtuzumab\u2010ozogamicin (GO) 3 mg\/m<jats:sup>2<\/jats:sup> (FLAI\u20105). Patients achieving complete remission (CR) received a second course without fludarabine but with higher dose of idarubicin. Patients not achieving CR received an intensified second course. Patients not scheduled for early allogeneic bone marrow transplantation (HSCT) where planned to receive at least two courses of consolidation therapy with Ara\u2010C. Our double induction strategy significantly differs from described fludarabine\u2010containing regimens, as patients achieving CR receive a second course without fludarabine, to avoid excess toxicity, and Ara\u2010C consolidation is administrated at the reduced cumulative dose of 8 g\/m<jats:sup>2<\/jats:sup> per cycle. Toxicity is a major concern in fludarabine containing induction, including the recent Medical Research Council AML15 fludarabine, cytarabine, idaraubicin and G\u2010CSF (FLAG\u2010Ida) arm, and, despite higher anti\u2010leukemic efficacy, only a minority of patients is able to complete the full planned program. In this article, we show that our therapeutic program is generally well tolerated, as most patients were able to receive subsequent therapy at full dose and in a timely manner, with a 30\u2010day mortality of 4.8%. The omission of fludarabine in the second course did not reduce efficacy, as a CR rate of 83% was achieved and 3\u2010year disease\u2010free survival and overall survival (OS) were 49.6% and 50.9%, respectively. Our experience shows that FLAI\u20105\/Ara\u2010C\u2009+\u2009Ida double induction followed by risk\u2010oriented consolidation therapy can result in good overall outcome with acceptable toxicity. Am. J. Hematol. 91:755\u2013762, 2016. \u00a9 2016 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.24391","type":"journal-article","created":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T15:46:46Z","timestamp":1460821606000},"page":"755-762","source":"Crossref","is-referenced-by-count":21,"title":["High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk\u2010oriented consolidation: A critical review of a 10\u2010year, single\u2010center experience in younger, non M3 AML patients"],"prefix":"10.1002","volume":"91","author":[{"given":"Fabio","family":"Guolo","sequence":"first","affiliation":[{"name":"Hematology Clinic, Department of Internal Medicine (DiMI) University of Genoa, IRCCS AOU S. Martino\u2010IST Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Minetto","sequence":"additional","affiliation":[{"name":"Hematology Clinic, Department of Internal Medicine (DiMI) University of Genoa, IRCCS AOU S. Martino\u2010IST Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marino","family":"Clavio","sequence":"additional","affiliation":[{"name":"Hematology Clinic, Department of Internal Medicine (DiMI) University of Genoa, IRCCS AOU S. Martino\u2010IST Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Miglino","sequence":"additional","affiliation":[{"name":"Hematology Clinic, Department of Internal Medicine (DiMI) University of Genoa, IRCCS AOU S. Martino\u2010IST Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Di Grazia","sequence":"additional","affiliation":[{"name":"Second Division of Hematology and Bone Marrow Transplantation IRCCS AOU S. Martino\u2010IST Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Ballerini","sequence":"additional","affiliation":[{"name":"Hematology Clinic, Department of Internal Medicine (DiMI) University of Genoa, IRCCS AOU S. Martino\u2010IST Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordana","family":"Pastori","sequence":"additional","affiliation":[{"name":"Hematology Clinic, Department of Internal Medicine (DiMI) University of Genoa, IRCCS AOU S. Martino\u2010IST Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Guardo","sequence":"additional","affiliation":[{"name":"Hematology Clinic, Department of Internal Medicine (DiMI) University of Genoa, IRCCS AOU S. Martino\u2010IST Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[{"name":"Hematology Clinic, Department of Internal Medicine (DiMI) University of Genoa, IRCCS AOU S. Martino\u2010IST Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Kunkl","sequence":"additional","affiliation":[{"name":"Service of Flow\u2010Cytometry, Department of Pathology IRCCS AOU S. Martino\u2010IST Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Fugazza","sequence":"additional","affiliation":[{"name":"Hematology Clinic, Department of Internal Medicine (DiMI) University of Genoa, IRCCS AOU S. Martino\u2010IST Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Rebesco","sequence":"additional","affiliation":[{"name":"Pharmacology Division IRCCS AOU S. Martino\u2010IST Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Sessarego","sequence":"additional","affiliation":[{"name":"Hematology Clinic, Department of Internal Medicine (DiMI) University of Genoa, IRCCS AOU S. Martino\u2010IST Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Massimo","family":"Lemoli","sequence":"additional","affiliation":[{"name":"Hematology Clinic, Department of Internal Medicine (DiMI) University of Genoa, IRCCS AOU S. Martino\u2010IST Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bacigalupo","sequence":"additional","affiliation":[{"name":"Second Division of Hematology and Bone Marrow Transplantation IRCCS AOU S. Martino\u2010IST Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gobbi","sequence":"additional","affiliation":[{"name":"Hematology Clinic, Department of Internal Medicine (DiMI) University of Genoa, IRCCS AOU S. Martino\u2010IST Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,15]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.2964"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70281-5"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.9088"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23404"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406184"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-354563"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70180-3"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.05.029"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.176"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004383"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301689"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235358"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.4738"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-254441"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.7.2322"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074306"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-623447"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00948.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.1.116"},{"key":"e_1_2_7_21_1","first-page":"513","article-title":"High efficacy of fludarabine\u2010containing therapy (FLAG\u2010FLANG) in poor risk acute myeloid leukemia","volume":"81","author":"Clavio M","year":"1996","journal-title":"Haematologica"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109057929"},{"key":"e_1_2_7_23_1","first-page":"481","article-title":"Fludarabine, ARA\u2010C, Idarubicin and G\u2010CSF (FLAG\u2010Ida), high dose ARA\u2010C and early stem cell transplant. A feasible and effective therapeutic strategy for de novo AML patients","volume":"21","author":"Clavio M","year":"2002","journal-title":"J Exper and Clin Cancer Res"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.4874"},{"key":"e_1_2_7_25_1","first-page":"1896","article-title":"Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease","volume":"9","author":"Macedo A","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_7_26_1","first-page":"993","article-title":"Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: Implications for minimal residual disease studies","volume":"9","author":"Macedo A","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP5TSD3DZXFLCX"},{"key":"e_1_2_7_28_1","first-page":"1:5195","article-title":"Real\u2010time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European Leukemia Net study","author":"Cilloni D","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.681658"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0359"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404149"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401130"},{"key":"e_1_2_7_33_1","volume-title":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.13"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.93"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.100784"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05745.x"},{"key":"e_1_2_7_38_1","first-page":"386","article-title":"Fludarabine containing induction increases minimal residual disease clearance and improves survival in AML patients with concomitant NPM1 and FLT3\u2010ITD mutations","volume":"100","author":"Guolo F","year":"2015","journal-title":"Haematologica"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.05.011"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950200207"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273243"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1780-7"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1746"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.114611"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.0371"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.07.005"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-551911"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24391","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24391","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T14:56:13Z","timestamp":1695480973000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,15]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1002\/ajh.24391"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24391","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,15]]}}}